Targeting Metabolic Vulnerabilities Reveals Hexokinase 2 as a Key Mediator of Resistance to Osimertinib in Non-Small Cell Lung Cancer Models.
- DOI
- 10.1021/acsptsci.5c00235
- Published
- 2025 Aug 8
- Container
- ACS pharmacology & translational science
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1021/acsptsci.5c00235,
title = {Targeting Metabolic Vulnerabilities Reveals Hexokinase 2 as a Key Mediator of Resistance to Osimertinib in Non-Small Cell Lung Cancer Models.},
author = {Guo Y and Huang D and Zhou Y and Ran M and Zhang S and Tam KY},
year = {2025},
journal = {ACS pharmacology \& translational science},
doi = {10.1021/acsptsci.5c00235},
url = {https://doi.org/10.1021/acsptsci.5c00235}
}RIS
TY - JOUR TI - Targeting Metabolic Vulnerabilities Reveals Hexokinase 2 as a Key Mediator of Resistance to Osimertinib in Non-Small Cell Lung Cancer Models. AU - Guo Y AU - Huang D AU - Zhou Y AU - Ran M AU - Zhang S AU - Tam KY PY - 2025 JO - ACS pharmacology & translational science DO - 10.1021/acsptsci.5c00235 UR - https://doi.org/10.1021/acsptsci.5c00235 ER -
APA
Y, G., D, H., Y, Z., M, R., S, Z., & KY, T. (2025). Targeting Metabolic Vulnerabilities Reveals Hexokinase 2 as a Key Mediator of Resistance to Osimertinib in Non-Small Cell Lung Cancer Models.. ACS pharmacology & translational science. https://doi.org/10.1021/acsptsci.5c00235
Source records
- pubmed · retrieved 2026-09-25T02:19:03.013Z